BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23329375)

  • 1. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.
    Løseth S; Voermans NC; Torbergsen T; Lillis S; Jonsrud C; Lindal S; Kamsteeg EJ; Lammens M; Broman M; Dekomien G; Maddison P; Muntoni F; Sewry C; Radunovic A; de Visser M; Straub V; van Engelen B; Jungbluth H
    J Neurol; 2013 Jun; 260(6):1504-10. PubMed ID: 23329375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.
    Jungbluth H; Lillis S; Zhou H; Abbs S; Sewry C; Swash M; Muntoni F
    Neuromuscul Disord; 2009 May; 19(5):344-7. PubMed ID: 19303294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RYR1-related myopathies: a wide spectrum of phenotypes throughout life.
    Snoeck M; van Engelen BG; Küsters B; Lammens M; Meijer R; Molenaar JP; Raaphorst J; Verschuuren-Bemelmans CC; Straathof CS; Sie LT; de Coo IF; van der Pol WL; de Visser M; Scheffer H; Treves S; Jungbluth H; Voermans NC; Kamsteeg EJ
    Eur J Neurol; 2015 Jul; 22(7):1094-112. PubMed ID: 25960145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre.
    Samões R; Oliveira J; Taipa R; Coelho T; Cardoso M; Gonçalves A; Santos R; Melo Pires M; Santos M
    J Neuromuscul Dis; 2017; 4(1):67-76. PubMed ID: 28269792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations.
    Knuiman GJ; Küsters B; Eshuis L; Snoeck M; Lammens M; Heytens L; De Ridder W; Baets J; Scalco RS; Quinlivan R; Holton J; Bodi I; Wraige E; Radunovic A; von Landenberg C; Reimann J; Kamsteeg EJ; Sewry C; Jungbluth H; Voermans NC
    J Neurol; 2019 Apr; 266(4):876-887. PubMed ID: 30788618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene.
    Jungbluth H; Zhou H; Hartley L; Halliger-Keller B; Messina S; Longman C; Brockington M; Robb SA; Straub V; Voit T; Swash M; Ferreiro A; Bydder G; Sewry CA; Müller C; Muntoni F
    Neurology; 2005 Dec; 65(12):1930-5. PubMed ID: 16380615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.
    Shaaban S; Ramos-Platt L; Gilles FH; Chan WM; Andrews C; De Girolami U; Demer J; Engle EC
    JAMA Ophthalmol; 2013 Dec; 131(12):1532-40. PubMed ID: 24091937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].
    Lunardi J; Monnier N
    Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S70-7. PubMed ID: 15269663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
    Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
    Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene.
    Dowling JJ; Lillis S; Amburgey K; Zhou H; Al-Sarraj S; Buk SJ; Wraige E; Chow G; Abbs S; Leber S; Lachlan K; Baralle D; Taylor A; Sewry C; Muntoni F; Jungbluth H
    Neuromuscul Disord; 2011 Jun; 21(6):420-7. PubMed ID: 21514828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.
    Vladutiu GD; Isackson PJ; Kaufman K; Harley JB; Cobb B; Christopher-Stine L; Wortmann RL
    Mol Genet Metab; 2011; 104(1-2):167-73. PubMed ID: 21795085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Functional Analysis of RYR1 Variants in a Family with a Suspected Myopathy and Associated Malignant Hyperthermia.
    Schiemann AH; Roesl C; Pollock N; Langton E; Bulger T; Stowell KM
    J Neuromuscul Dis; 2020; 7(1):51-60. PubMed ID: 31903994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.
    Rueffert H; Olthoff D; Deutrich C; Schober R; Froster UG
    Am J Med Genet A; 2004 Jan; 124A(3):248-54. PubMed ID: 14708096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.
    Kraeva N; Heytens L; Jungbluth H; Treves S; Voermans N; Kamsteeg E; Ceuterick-de Groote C; Baets J; Riazi S
    Neuromuscul Disord; 2015 Jul; 25(7):567-76. PubMed ID: 25958340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility.
    Taylor A; Lachlan K; Manners RM; Lotery AJ
    J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.